Tag: Dr Cyrus Karkaria

Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited shares his views on the current market trends and growth prospects of Indian biosimilars industry, company’s key offerings, ongoing initiatives, and future plans

The Cover Story analyzes the blockbuster opportunity for India's biopharma industry. Read interviews of Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited; Sachin Joshi, MD & Founder, PharmNXT Biotech; Mandeep Singh Kumar, MD and Vice President, Medtronic India; and Harshvardhan Bhagchandka, President, IPL Biologicals

This product will be marketed under the brand name Armlupeg® and manufactured at Lupin’s Biotech facility at Pune, India

The event organized by the International Contract Pharma Association (ICPA) in San Deigo witnessed deliberations on drug discovery services scenario in India

Happening on the sidelines of US BIO 2024, the event will see top experts sharing their perspective on how international stakeholders can benefit from outsourcing their requirements to India

Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited

This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.